CU20150176A7 - Derivados de prodroga de triazolpiridinas sustituídas - Google Patents

Derivados de prodroga de triazolpiridinas sustituídas

Info

Publication number
CU20150176A7
CU20150176A7 CUP2015000176A CU20150176A CU20150176A7 CU 20150176 A7 CU20150176 A7 CU 20150176A7 CU P2015000176 A CUP2015000176 A CU P2015000176A CU 20150176 A CU20150176 A CU 20150176A CU 20150176 A7 CU20150176 A7 CU 20150176A7
Authority
CU
Cuba
Prior art keywords
derivatives
triazolpiridines
substituted
supply
mps
Prior art date
Application number
CUP2015000176A
Other languages
English (en)
Inventor
Volker Schulze
Hans-Georg Lerchen
Donald Bierer
Antje Margret Wengner
Gerhard Siemeister
Dr Philip Lienau
Ursula Krenz
Dr Dirk Kosemund
Dr Detlef Stöckigt
Dr Michael Brüning
Dr Ulrich Lücking
Ildiko Terebesi
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Publication of CU20150176A7 publication Critical patent/CU20150176A7/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • C07K5/06052—Val-amino acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06086—Dipeptides with the first amino acid being basic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Derivados de prodroga de inhibidores de la quinasa Mps-1, procesos para su preparación y su uso en el tratamiento y/o la profilaxis de enfermedades.
CUP2015000176A 2013-06-11 2015-12-11 Derivados de prodroga de triazolpiridinas sustituídas CU20150176A7 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13171508 2013-06-11
PCT/EP2014/061779 WO2014198647A2 (en) 2013-06-11 2014-06-06 Prodrug derivatives of substituted triazolopyridines

Publications (1)

Publication Number Publication Date
CU20150176A7 true CU20150176A7 (es) 2016-05-30

Family

ID=48576905

Family Applications (1)

Application Number Title Priority Date Filing Date
CUP2015000176A CU20150176A7 (es) 2013-06-11 2015-12-11 Derivados de prodroga de triazolpiridinas sustituídas

Country Status (35)

Country Link
US (1) US9586958B2 (es)
EP (1) EP3008062B1 (es)
JP (1) JP2016526534A (es)
KR (1) KR20160019492A (es)
CN (1) CN105377848A (es)
AP (1) AP2015008898A0 (es)
AR (1) AR096585A1 (es)
AU (1) AU2014280356A1 (es)
CA (1) CA2914745A1 (es)
CL (1) CL2015003605A1 (es)
CR (1) CR20150659A (es)
CU (1) CU20150176A7 (es)
DK (1) DK3008062T3 (es)
DO (1) DOP2015000299A (es)
EA (1) EA201600002A1 (es)
ES (1) ES2626790T3 (es)
HK (1) HK1221955A1 (es)
HR (1) HRP20170717T1 (es)
HU (1) HUE033131T2 (es)
IL (1) IL242847A0 (es)
LT (1) LT3008062T (es)
MA (1) MA38654B1 (es)
MX (1) MX2015017119A (es)
NI (1) NI201500176A (es)
PE (1) PE20160156A1 (es)
PH (1) PH12015502746A1 (es)
PL (1) PL3008062T3 (es)
PT (1) PT3008062T (es)
RS (1) RS56034B1 (es)
SG (1) SG11201509858QA (es)
SI (1) SI3008062T1 (es)
TN (1) TN2015000545A1 (es)
UY (1) UY35610A (es)
WO (1) WO2014198647A2 (es)
ZA (1) ZA201508868B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA41136A (fr) * 2014-12-09 2017-10-17 Bayer Pharma AG Composés pour le traitement d'un cancer
EP3283642B1 (en) 2015-04-17 2023-10-11 Netherlands Translational Research Center Holding B.V. Prognostic biomarkers for ttk inhibitor chemotherapy
WO2017176620A2 (en) 2016-04-04 2017-10-12 Chemocentryx, Inc. SOLUBLE C5aR ANTAGONISTS
AU2022408915B2 (en) * 2021-12-15 2026-05-14 Sillajen, Inc. Methods of treating neoplastic diseases

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR199900389T2 (xx) 1996-08-28 2000-06-21 Pfizer Inc. �kame edilmi� 6,5-hetero-bisiklik t�revleri.
AU742739B2 (en) 1997-05-28 2002-01-10 Aventis Pharmaceuticals Inc. Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56 lck tyrosine kinases
US6514989B1 (en) 2001-07-20 2003-02-04 Hoffmann-La Roche Inc. Aromatic and heteroaromatic substituted 1,2,4-triazolo pyridine derivatives
JP2004346016A (ja) 2003-05-22 2004-12-09 Otsuka Chemical Co Ltd トリフルオロメチルキノキサリン化合物、その製造方法、及び有害生物防除剤
JP4499721B2 (ja) 2003-06-30 2010-07-07 ヒフ バイオ，インク． 化合物、組成物および方法
MX2007004179A (es) 2004-10-07 2007-06-07 Warner Lambert Co Derivados de triazolpiridina como agentes antibacterianos.
US20070049591A1 (en) 2005-08-25 2007-03-01 Kalypsys, Inc. Inhibitors of MAPK/Erk Kinase
US7723336B2 (en) 2005-09-22 2010-05-25 Bristol-Myers Squibb Company Fused heterocyclic compounds useful as kinase modulators
US20070078136A1 (en) 2005-09-22 2007-04-05 Bristol-Myers Squibb Company Fused heterocyclic compounds useful as kinase modulators
WO2007065010A2 (en) 2005-12-02 2007-06-07 Hif Bio, Inc. Anti-angiogenesis compounds
DE602007006010D1 (de) 2006-05-31 2010-06-02 Galapagos Nv Triazolopyrazinverbindungen zur behandlung von degenerations- und entzündungskrankheiten
CA2658725A1 (en) 2006-08-16 2008-02-21 Exelixis, Inc. Using pi3k and mek modulators in treatments of cancer
ES2549862T3 (es) 2006-08-30 2015-11-02 Cellzome Limited Derivados de triazol como inhibidores de quinasa
PE20090288A1 (es) 2007-05-10 2009-04-03 Smithkline Beecham Corp Derivados de quinoxalina como inhibidores de la pi3 quinasa
EP2178868A1 (en) 2007-07-18 2010-04-28 Novartis Ag Bicyclic heteroaryl compounds and their use as kinase inhibitors
WO2009021083A1 (en) 2007-08-09 2009-02-12 Smithkline Beecham Corporation Quinoxaline derivatives as pi3 kinase inhibitors
MX2010002115A (es) 2007-08-23 2010-06-01 Aztrazeneca Ab 2-anilinopurin-8-onas como inhibidores de ttk/mps1 para el tratamiento de trastornos .proliferativos.
MX2010002312A (es) 2007-08-31 2010-03-18 Merck Serono Sa Compuestos de triazolopiridina y su uso como inhibidores de cinasa reguladora de señal de apoptosis.
GB0719803D0 (en) 2007-10-10 2007-11-21 Cancer Rec Tech Ltd Therapeutic compounds and their use
EP2222674B8 (en) 2007-11-27 2016-01-06 Cellzome Limited Amino triazoles as pi3k inhibitors
JP5599783B2 (ja) 2008-05-30 2014-10-01 アムジエン・インコーポレーテツド Ｐｉ３キナーゼの阻害薬
TWI491610B (zh) 2008-10-09 2015-07-11 必治妥美雅史谷比公司 作為激酶抑制劑之咪唑并嗒腈
WO2010092015A1 (en) 2009-02-10 2010-08-19 Cellzome Limited Urea triazololo [1, 5-a] pyridine derivatives as pi3k inhibitors
CN102317288A (zh) 2009-02-13 2012-01-11 佛维雅制药公司 作为激酶抑制剂的[1,2,4]三唑并[1,5-a]吡啶
ES2547328T3 (es) 2009-04-29 2015-10-05 Bayer Intellectual Property Gmbh Imidazoquinoxalinas sustituidas
TW201107329A (en) 2009-07-30 2011-03-01 Oncotherapy Science Inc Fused imidazole derivative having ttk inhibitory action
JP5728683B2 (ja) 2009-09-04 2015-06-03 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ チロシンスレオニンキナーゼ阻害剤としての置換アミノキノキサリン
EP2343294A1 (en) * 2009-11-30 2011-07-13 Bayer Schering Pharma AG Substituted triazolopyridines
EP2343295A1 (en) * 2009-11-30 2011-07-13 Bayer Schering Pharma AG Triazolopyridine derivates
EP2343297A1 (en) * 2009-11-30 2011-07-13 Bayer Schering Pharma AG Triazolopyridines
AU2011206635B2 (en) 2010-01-15 2015-01-22 Cellzome Limited Novel substituted triazole derivatives as gamma secretase modulators
US20110190269A1 (en) 2010-02-01 2011-08-04 Karlheinz Baumann Gamma secretase modulators
UY33452A (es) * 2010-06-16 2012-01-31 Bayer Schering Pharma Ag Triazolopiridinas sustituidas
TWI541243B (zh) 2010-09-10 2016-07-11 拜耳知識產權公司 經取代咪唑并嗒
US20140120087A1 (en) 2011-04-21 2014-05-01 Bayer Intellectual Property Gmbh Triazolopyridines
UA112096C2 (uk) * 2011-12-12 2016-07-25 Байєр Інтеллектуал Проперті Гмбх Заміщені триазолопіридини та їх застосування як інгібіторів ttk
JP6166289B2 (ja) 2012-03-14 2017-07-19 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ 置換イミダゾピリダジン
BR112015000308A2 (pt) * 2012-07-10 2017-06-27 Bayer Pharma AG método para preparo de triazolopiridinas substituídas
AR096469A1 (es) * 2013-06-06 2015-12-30 Bayer Pharma AG Composiciones farmacéuticas que comprenden compuestos del tipo triazolpiridinas
CA2914521A1 (en) * 2013-06-07 2014-12-11 Bayer Pharma Aktiengesellschaft Substituted triazolopyridines having activity as mps-1 inhibitors
CN105246891A (zh) * 2013-06-10 2016-01-13 拜耳制药股份公司 用于治疗癌症的新化合物
EP3007692A1 (en) * 2013-06-11 2016-04-20 Bayer Pharma Aktiengesellschaft Combinations for the treatment of cancer comprising a mps-1 kinase inhibitor and a mitotic inhibitor

Also Published As

Publication number Publication date
JP2016526534A (ja) 2016-09-05
RS56034B1 (sr) 2017-09-29
WO2014198647A3 (en) 2015-02-05
HK1221955A1 (zh) 2017-06-16
HRP20170717T1 (hr) 2017-07-28
PH12015502746A1 (en) 2016-03-21
US9586958B2 (en) 2017-03-07
NI201500176A (es) 2016-01-06
IL242847A0 (en) 2016-02-01
PE20160156A1 (es) 2016-04-20
CN105377848A (zh) 2016-03-02
SG11201509858QA (en) 2015-12-30
TN2015000545A1 (en) 2017-04-06
LT3008062T (lt) 2017-06-12
MA38654B1 (fr) 2018-11-30
DOP2015000299A (es) 2016-03-15
ZA201508868B (en) 2017-08-30
US20160207915A1 (en) 2016-07-21
AP2015008898A0 (en) 2015-12-31
PT3008062T (pt) 2017-06-07
AR096585A1 (es) 2016-01-20
HUE033131T2 (en) 2017-11-28
CL2015003605A1 (es) 2016-06-24
ES2626790T3 (es) 2017-07-26
EA201600002A1 (ru) 2016-06-30
SI3008062T1 (sl) 2017-06-30
EP3008062B1 (en) 2017-04-05
CR20150659A (es) 2016-01-29
DK3008062T3 (en) 2017-06-12
WO2014198647A2 (en) 2014-12-18
CA2914745A1 (en) 2014-12-18
EP3008062A2 (en) 2016-04-20
MX2015017119A (es) 2016-04-06
UY35610A (es) 2015-01-30
KR20160019492A (ko) 2016-02-19
AU2014280356A1 (en) 2015-12-24
PL3008062T3 (pl) 2017-08-31

Similar Documents

Publication Publication Date Title
SV2018005610A (es) Derivados de oxopiridina sustituidos
MX386935B (es) Profármacos de fumaratos y su uso en el tratamiento de diferentes enfermedades.
CL2015001985A1 (es) Compuestos de tiazolcarboxamidas y piridinacarboxamida, inhibidores de quinasa pim.
CL2016002735A1 (es) Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso para tratar cáncer
DOP2015000274A (es) Compuestos químicos
MX2020012165A (es) Derivados de bencimidazol como inhibidores de tirosina cinasa erbb para el tratamiento del cancer.
CL2016002027A1 (es) Ciclopropilamina como inhibidor de la lsd1
CL2015003686A1 (es) Derivados de pirrolo[3,2-d]pirimidina para el tratamiento de infecciones víricas y otras enfermedades
CL2016000153A1 (es) Derivados de pirrolamida sustituidos con glioxamida y su uso como medicamentos para el tratamiento de la hepatitis b
CR20150472A (es) USO DE DERIVADOS DE PIRAZOLOPIRIMIDINA PARA EL TRATAMIENTO DE TRANSTORNOS RELACIONADOS CON LA PI3Kd
CL2014001793A1 (es) Compuestos derivados de 1,3,5-triazinas sustituidas y sus sales, como inhibidores de la idh2 mutante; composicion farmaceutica que los comprende; y su uso para el tratamiento del cancer.
CL2018003444A1 (es) Derivados de adenosina para uso en el tratamiento del cancer.
CL2016003214A1 (es) Derivados de la indolizina como inhibidores de las fosfoinositido-3 quinasas
CL2016003074A1 (es) Compuestos derivados de 2-oxi-2-fenil-n-5-pirrolidin-3-ilamino-1,3,4-tiadiazol-2-ilacetamida, inhibidores gls1 composición farmacéutica y su uso para tratar el cáncer.
CL2016001151A1 (es) Derivados de purina 2,6-sustituidos y su uso en el tratamiento de trastorno proliferativos.
NI201500115A (es) Estra-1,3,5(10), 16-tetraeno-3-carboxamidas para la inhibición de la 17b-hidroxiesteroide deshidrogenasa (akr1 c3)
NI201500175A (es) Compuestos nuevos para el tratamiento del cáncer
CL2016002151A1 (es) Derivados de piridazina para uso en la prevención o el tratamiento de un trastorno atáxico
MX2018005987A (es) Compuestos heterociclicos para el tratamiento de enfermedades.
CR20150659A (es) Derivados de prodroga de triazolpiridinas sustituidas
CL2016001054A1 (es) Compuestos para el tratamiento de diabetes y complicaciones de enfermedades derivadas de la misma
NI201700072A (es) Compuestos para tratar el cáncer.
MX373441B (es) Derivados de indol-urea glucopiranosil-sustituido y su uso como inhibidores sglt.
CR20140489A (es) Uso de 18-metil-15b, 16b-metilen-19-nor-20-espirox-4-en-3-onas en el tratamiento de menorragia, y sistemas intrauterinos que comprenden 18-metil-15b, 16b-metilen-19-nor-20-espirox-4-en-3-onas para el tratamiento de t
DOP2015000290A (es) Benzoxazoles sustituidos